TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
ORLANDO, Fla., March 6, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).
TNI BioTech has spent the last year developing a manufacturing and distribution network for sale of LDN into emerging nations and has had discussions with the FDA and EMA to begin clinical trials in the United States.
The Company has considered whether to separate (1) the development activities of the Company, and (2) the manufacturing and distribution of its novel therapies into emerging nations. Due to the differences in experience required to run a development business and a distribution business, the Company believes that now is the right time to separate these business lines before beginning its clinical trials and platform development of the biopharmaceuticals business. While both businesses have moved forward this year under single management, they have distinctly different business models, sales channels, customers, capital requirements and the need for very different management.
TNI BioTech, Inc. Subsidiary Granted Certificate of Free Sale by Nicaraguan Minister of Health for Low Dose Naltrexone
Certificate allows for product to be exported by TNI BioTech's Nicaraguan manufacturing facility
White Plains, NEW YORK - December 3, 2013 - TNI BioTech Inc (OTCQB:TNIB) today announced that the Nicaraguan Ministry of Health has granted a certificate of free sale to the company's wholly-owned subsidiary, TNI BioTech International Ltd., for TNI BioTech's Low Dose Naltrexone product (LDN) for the treatment of patients with autoimmune diseases HIV/AIDS, Crohn's Disease, Multiple Sclerosis and certain cancers.
TNI Biotech was awarded for “Corporate Responsibility” by Rosa Whitaker of the Whitaker Group, in recognition of the company’s efforts toward affordable, accessible and sustainable healthcare in Africa. TNI Biotech is focused on developing innovative and affordable immunotherapy treatment for diseases such as AIDS/HIV, cancer and Crohn’s disease.